One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Cerus Corporation logo
Cerus Corporation CERS
$ 2.39 3.46%
report update icon

Quarterly report 2026-Q2
added 07-30-2026

Cerus Corporation Financial Ratios 2025-2008 | CERS

Brief overview of Cerus Corporation's valuation multiples

Ratios are assessed across five available annual reports in the 2021–2025 interval.

Key multiples at the end of the period are P/S 2.12x (median 2.12x), P/B 7.63x (median 6.69x). The multiple basket looks neutral against its history, differing from median levels by roughly +7%.

Returns on assets and capital are represented by ROE -24.3%, ROA -7%, ROCE -13.5%. Losses and negative capital returns make ordinary P/E-like references unstable or inapplicable.

PEG is 0.95x. Price relative to expected growth is in a moderate range.

Cash turnover speed was broadly preserved, with the cycle moving from 53 days to 47 days.

Overall picture

Cerus Corporation's valuation and business quality look relatively balanced, with no pronounced distortion in either direction.

Annual Financial Ratios Cerus Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

P/E

-31.7 -14.4 -9.5 -10.7 -21.5 -19.0 -8.2 -13.1 -8.5 -6.7 -9.3 -10.3 -9.8 -10.8 -7.8 -7.6 -1.7 -

P/S

2.1 1.5 1.9 2.4 7.3 9.9 6.2 9.9 10.0 10.7 15.2 11.0 10.7 4.7 4.0 5.6 2.3 -

EPS

-0.1 -0.1 -0.2 -0.2 -0.3 -0.4 -0.5 -0.4 -0.6 -0.6 -0.6 -0.5 -0.6 -0.3 -0.3 -0.4 -0.7 -

EV (Enterprise Value)

632 M 425 M 490 M 573 M 1.27 B 1.21 B 657 M 803 M 561 M 443 M 495 M 417 M 435 M 174 M 134 M 124 M 23.4 M -10.3 M

EBITDA per Share

-0.04 -0.07 -0.15 -0.18 -0.27 -0.34 -0.456 -0.407 -0.53 -0.6 -0.634 -0.593 -0.416 -0.314 -0.327 -0.37 -0.66 -

EV/EBITDA

-87.2 -34.3 -17.8 -18.4 -24.7 -19.8 -9.3 -14.1 -9.3 -6.8 -7.7 -8.7 -14.2 -8.9 -7.3 -8.2 -1.0 -

PEG

0.95 0.48 0.57 0.59 1.56 1.77 0.51 -0.61 -0.88 0.97 0.81 -0.55 0.08 -0.63 -0.47 - - -

P/B

7.6 5.3 6.7 6.7 13.6 10.9 10.2 8.9 13.2 7.3 5.5 9.6 9.9 9.0 7.2 5.4 - -

P/CF

102.4 26.5 -8.3 -17.9 -34.4 -27.1 -7.8 -23.3 -9.8 -7.8 -10.1 -9.5 -15.5 -12.2 -8.4 -9.0 -2.8 -

ROE %

-24.33 -37.26 -71.20 -63.27 -63.51 -57.66 -124.88 -68.11 -155.59 -108.86 -58.95 -93.34 -101.27 -83.30 -92.73 -71.26 -112.53 -

ROA %

-7.04 -10.41 -18.96 -19.62 -22.89 -27.03 -43.04 -35.22 -61.67 -60.79 -40.06 -47.39 -51.97 -32.54 -37.43 -35.11 - -

ROCE %

-13.52 -25.34 -57.08 -50.41 -57.16 -56.19 -57.49 -49.64 -76.59 -80.03 -51.95 -84.62 -64.38 -74.23 -65.66 -67.24 -111.12 -

Current Ratio

1.4 1.4 1.4 1.5 1.6 1.9 2.5 2.8 3.9 3.5 6.0 2.6 2.0 1.7 1.9 2.0 - -

DSO

47.0 59.2 68.3 57.7 53.0 60.8 65.7 42.0 88.3 63.8 61.8 55.1 56.4 44.2 67.3 37.8 - -

DIO

- - - - - - 212.9 156.2 234.2 225.4 168.2 257.6 211.0 180.2 126.9 - - -

DPO

- - - - - - 242.3 214.6 177.8 154.4 81.2 170.2 91.6 127.2 92.2 - - -

Operating Cycle

47.0 59.2 68.3 57.7 53.0 60.8 278.6 198.2 322.5 289.2 230.0 312.7 267.3 224.4 194.2 37.8 - -

Cash Conversion Cycle

47.0 59.2 68.3 57.7 53.0 60.8 36.3 -16.3 144.7 134.8 148.8 142.5 175.7 97.2 102.1 37.8 - -

All numbers in USD currency

Quarterly Financial Ratios Cerus Corporation

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.01 -0.01 - -0.03 -0.04 -0.02 -0.03 -0.05 -0.04 -0.07 -0.09 - -0.05 -0.05 -0.07 - -0.07 -0.09 -0.1 - -0.08 -0.09 -0.1 -0.12 -0.13 -0.13 -0.14 -0.12 -0.11 -0.1 -0.11 -0.1 -0.12 -0.16 -0.18 -0.13 -0.14 -0.18 -0.17 -0.15 -0.16 -0.17 -0.1 -0.26 -0.14 -0.1 - -0.08 -0.29 -0.1 -0.17 -0.03 -0.06 -0.04 -0.17 -0.16 0.05 -0.13 -0.11

EBITDA per Share

- - - - -0.03 - - -0.04 - - -0.08 - -0.03 -0.04 -0.05 - -0.05 -0.08 -0.09 - -0.07 -0.08 -0.09 - -0.11 -0.11 -0.11 - -0.09 -0.09 -0.1 - -0.1 -0.15 -0.17 - -0.13 -0.16 -0.15 - -0.15 -0.15 -0.15 - -0.14 -0.14 -0.12 -0.11 -0.11 -0.1 -0.08 -0.06 -0.07 -0.08 -0.08 -0.06 -0.04 -0.11 -0.08

ROE %

-16.95 -26.48 -29.45 -40.90 -49.92 -51.02 -71.30 -86.04 -78.18 -74.28 -63.88 -37.66 -53.00 -59.78 -67.70 -52.42 -66.04 -65.03 -62.65 -43.81 -73.47 -91.34 -107.80 -124.88 -114.39 -99.69 -84.62 -68.11 -78.43 -96.10 -124.25 -155.59 -149.45 -139.87 -127.44 -108.86 -101.07 -92.73 -78.15 -58.95 -91.99 -101.36 -102.78 -93.34 -58.42 -80.42 -77.85 -101.27 -96.55 -66.76 -61.03 -83.30 -116.56 -86.11 -111.13 -92.73 12.34 -35.00 -27.84

ROA %

-4.86 -7.16 -7.97 -11.07 -13.52 -13.31 -18.44 -22.79 -21.60 -23.61 -22.62 -15.15 -22.04 -18.10 -26.01 -20.48 -26.86 -27.90 -28.45 -20.54 -30.76 -35.23 -39.12 -43.04 -42.73 -40.56 -38.07 -35.22 -36.99 -41.97 -51.23 -61.67 -63.02 -63.26 -63.43 -60.79 -58.33 -55.69 -49.59 -40.08 -54.17 -56.08 -53.90 -47.39 -29.74 -41.17 -39.95 -51.97 -48.45 -30.94 -26.77 -32.54 -46.08 -34.02 -44.25 -37.43 4.98 -14.13 -11.24

ROCE %

-7.34 -15.10 -16.34 -25.98 -35.71 -36.00 -56.75 -72.87 -67.02 -65.23 -54.95 -31.20 -44.93 -51.97 -60.82 -48.57 -62.04 -62.39 -60.13 -42.38 -72.10 -88.07 -102.16 -87.32 -103.42 -88.57 -74.93 -46.77 -78.57 -104.09 -135.68 -119.87 -144.55 -141.72 -126.66 -80.20 -97.28 -88.98 -75.18 -48.63 -75.97 -85.39 -91.21 -76.04 -94.28 -86.63 -76.74 -66.13 -66.72 -69.70 -78.20 -90.54 -89.91 -82.11 -87.42 -86.95 -14.86 -30.43 -23.46

Current Ratio

1.5 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.3 1.4 1.4 1.5 1.5 - 1.6 1.6 1.6 1.6 1.7 1.9 1.9 1.9 1.9 1.5 1.5 1.5 1.5 2.1 2.1 2.1 2.1 1.7 1.7 1.7 1.7 2.3 2.3 2.3 2.3 3.1 3.1 3.1 3.1 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 1.6 1.6 1.6 1.6 1.7 1.7 1.7 1.7

DSO

47.9 50.2 - - 53.5 - - - - - - - - - - - - - - - - - - - - - - - 51.9 51.8 - - 104.9 118.9 - - - - - - - - - - - - - - - - - - 49.1 44.0 54.8 - 60.1 82.4 -

DIO

- - - - - - - - - - - - - - - - 157.4 165.4 195.5 - 193.7 218.6 234.4 - 234.5 219.3 178.7 - 151.7 160.0 174.3 - 246.7 302.6 - - - - - - 177.4 - - - 239.9 - - - - - - - - - - - - - -

DPO

- - - - - - - - - - - - - - - - 148.1 159.1 192.2 - 201.7 227.7 254.4 - 267.0 249.6 220.7 - 208.4 219.8 184.1 - 187.2 229.7 - - - - - - 85.6 - - - 158.5 - - - - - - - - - - - - - -

Operating Cycle

- 50.2 - - 53.5 - - - - - - - - - - - 157.4 165.4 195.5 - 193.7 218.6 234.4 - 234.5 219.3 178.7 - 203.6 211.8 174.3 - 351.6 421.5 - - - - - - 177.4 - - - 239.9 - - - - - - - 49.1 44.0 54.8 - 60.1 82.4 -

Cash Conversion Cycle

- 50.2 - - 53.5 - - - - - - - - - - - 9.3 6.3 3.2 - -8.0 -9.0 -20.0 - -32.4 -30.3 -41.9 - -4.8 -8.0 -9.8 - 164.3 191.8 - - - - - - 91.8 - - - 81.4 - - - - - - - 49.1 44.0 54.8 - 60.1 82.4 -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Cerus Corporation, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Certara Certara
CERT
$ 10.18 4.04 % $ 1.63 B usaUSA
Flexion Therapeutics, Inc. Flexion Therapeutics, Inc.
FLXN
- - $ 459 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.02 2.0 % $ 119 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 116.28 -0.15 % $ 12.1 B usaUSA
CorMedix CorMedix
CRMD
$ 7.79 2.91 % $ 561 K usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 50.5 1.24 % $ 4.54 B schweizSchweiz
Greenwich LifeSciences Greenwich LifeSciences
GLSI
$ 16.57 2.03 % $ 224 M usaUSA
Champions Oncology Champions Oncology
CSBR
$ 4.85 0.83 % $ 67.1 M usaUSA
Heat Biologics, Inc. Heat Biologics, Inc.
HTBX
- -5.76 % $ 99.8 M usaUSA
Cue Biopharma Cue Biopharma
CUE
$ 18.95 11.21 % $ 1.8 B usaUSA
Kindred Biosciences, Inc. Kindred Biosciences, Inc.
KIN
- 0.11 % $ 419 M usaUSA
DBV Technologies S.A. DBV Technologies S.A.
DBVT
$ 9.62 1.48 % $ 1.34 B franceFrance
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 2.39 0.84 % $ 15.3 B australiaAustralia
Shineco, Inc. Shineco, Inc.
TYHT
- -3.90 % $ 97.2 M chinaChina
Actinium Pharmaceuticals Actinium Pharmaceuticals
ATNM
$ 1.38 -1.43 % $ 43.1 M usaUSA
Millendo Therapeutics, Inc. Millendo Therapeutics, Inc.
MLND
- -5.36 % $ 20.2 M usaUSA
DiaMedica Therapeutics DiaMedica Therapeutics
DMAC
$ 8.69 0.23 % $ 408 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 1.96 -2.49 % $ 24.1 M usaUSA
Dyadic International Dyadic International
DYAI
$ 0.4 3.87 % $ 14.5 M usaUSA
Intec Pharma Ltd Intec Pharma Ltd
NTEC
- -12.45 % $ 17.7 M israelIsrael
Edesa Biotech Edesa Biotech
EDSA
$ 2.85 1.06 % $ 16.2 M usaUSA
Progenity, Inc. Progenity, Inc.
PROG
- -3.47 % $ 164 M usaUSA
Lantern Pharma Lantern Pharma
LTRN
$ 0.68 4.28 % $ 7.41 M usaUSA
Strongbridge Biopharma plc Strongbridge Biopharma plc
SBBP
- 1.52 % $ 136 M usaUSA
Fennec Pharmaceuticals Fennec Pharmaceuticals
FENC
$ 10.38 -0.76 % $ 297 M usaUSA
Seneca Biopharma, Inc. Seneca Biopharma, Inc.
SNCA
- -1.19 % $ 28.7 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 0.94 0.81 % $ 62.8 M usaUSA
Inhibrx Inhibrx
INBX
$ 98.19 3.03 % $ 4.63 B usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
$ 49.3 -1.77 % $ 1.33 B usaUSA
ImmuCell Corporation ImmuCell Corporation
ICCC
$ 10.52 0.67 % $ 95 M usaUSA
Fulcrum Therapeutics Fulcrum Therapeutics
FULC
$ 3.7 -0.54 % $ 234 M usaUSA
Kamada Ltd. Kamada Ltd.
KMDA
$ 7.78 -0.89 % $ 448 M israelIsrael
IDEAYA Biosciences IDEAYA Biosciences
IDYA
$ 35.47 0.31 % $ 3.14 B usaUSA
InflaRx N.V. InflaRx N.V.
IFRX
$ 1.55 0.65 % $ 104 M germanyGermany
Immutep Limited Immutep Limited
IMMP
$ 3.28 0.61 % $ 4.78 B australiaAustralia
Mustang Bio Mustang Bio
MBIO
$ 0.38 0.9 % $ 1.87 M usaUSA
Kala Pharmaceuticals Kala Pharmaceuticals
KALA
$ 0.19 0.58 % $ 1.55 M usaUSA
Mereo BioPharma Group plc Mereo BioPharma Group plc
MREO
$ 0.29 -1.32 % $ 231 M britainBritain
Kiniksa Pharmaceuticals, Ltd. Kiniksa Pharmaceuticals, Ltd.
KNSA
$ 79.7 -4.17 % $ 5.91 B usaUSA
Karyopharm Therapeutics Karyopharm Therapeutics
KPTI
$ 0.42 18.35 % $ 4.59 K usaUSA
Seres Therapeutics Seres Therapeutics
MCRB
$ 2.3 -0.43 % $ 20.4 M usaUSA
MediWound Ltd. MediWound Ltd.
MDWD
$ 12.1 0.5 % $ 329 M israelIsrael
Precigen Precigen
PGEN
$ 6.6 -3.37 % $ 2.07 B usaUSA
PolyPid Ltd. PolyPid Ltd.
PYPD
$ 5.07 -1.55 % $ 82.9 M israelIsrael
Rocket Pharmaceuticals Rocket Pharmaceuticals
RCKT
$ 2.2 -5.98 % $ 244 M usaUSA
Avidity Biosciences Avidity Biosciences
RNA
$ 8.0 0.25 % $ 1.1 B usaUSA
Summit Therapeutics Summit Therapeutics
SMMT
$ 15.83 -1.62 % $ 11.8 B britainBritain
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
Генетико Генетико
GECO
- - - russiaRussia